Work

An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) + chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo + trastuzumab ± pembro in first-line metastatic HER2+ gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps4207

Authors: Kohei Shitara, Lin Shen, Jeeyun Lee, Paulo Marcelo Hoff, Elizabeth Catherine Smyth, Daniel Barrios, Kojiro Kobayashi, Yasuyuki Okuda, Takahiro Kamio, Yelena Y. Janjigian

Institutions: National Cancer Center Hospital East, Peking University Cancer Hospital, Samsung Medical Center, Universidade de São Paulo, Churchill Hospital, University of Oxford, Daiichi Sankyo (United States), Daiichi-Sankyo (Japan), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Gastric Cancer Management and Outcomes

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410815842

FWCI: 3.038

Cites:

Cited by: 5

Related to: 10